Determination of Mequitazine in Human Plasma by Gas-Chro-matography/Mass Spectrometry with Ion-Trap Detector and Its Pharmacokinetics after Oral Administration to Volunteers

  • Kwon Oh-Seung (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology(KIST)) ;
  • Kim Hye-Jung (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology(KIST)) ;
  • Pyo Heesoo (Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology(KIST)) ;
  • Chung Suk-Jae (College of Pharmacy, Seoul National University) ;
  • Chung Youn Bok (National Research Lab. of PK/PD, Biotechnology Research Institute, College of Pharmacy, Chungbuk National University)
  • Published : 2005.10.01

Abstract

The objective of this study was to develop an assay for mequitazine (MQZ) for the study of the bioavailability of the drug in human subjects. Using one mL of human plasma, the pH of the sample was adjusted and MQZ in the aqueous phase extracted with hexane; the organic layer was then evaporated to dryness, reconstituted and an aliquot introduced to a gas chromatograph/mass spectrometer (GC/MS) system with ion-trap detector. Inter- and intra-day precision of the assay were less than 15.1 and $17.7{\%}$, respectively; Inter- and intra-day accuracy were less than 8.91 and $18.6{\%}$, respectively. The limit of quantification for the current assay was set at 1 ng/mL. To determine whether the current assay is applicable in a pharmacokinetic study for MQZ in human, oral formulation containing 10 mg MQZ was administered to healthy male subjects and blood samples collected. The current assay was able to quantify MQZ levels in most of the samples. The maximum concentration ($C_{max}$ was 8.5 ng/mL, which was obtained at 10.1 h, with mean half-life of approximately 45.5 h. Under the current sampling protocol, the ratio of $AUC_{t{\rightarrow}last}$ to $AUC_{t{\rightarrow}{\infty}}$ was $934{\%}$, indicating that the blood collection time of 216 h is reasonable for MQZ. Therefore, these observations indicate that an assay for MQZ in human plasma is developed by using GC/MS with ion-trap detector and validated for the study of pharmacokinetics of single oral dose of 10 mg MQZ, and that the current study design for the bioavailability study is adequate for the drug.

Keywords

References

  1. EI-Ragehy, N. A., Badawey, A. M., and El-Khateeb, S. Z., Stability indicating methods for assay of mequitazine in presence of its degradate. J. Pharm. Biomed. Anal., 29 (1-2), 121-137 (2002) https://doi.org/10.1016/S0731-7085(02)00038-9
  2. Fourtillan, J. B., Girault, J., Bouquet, S., and Lefebvre, M. A., Determination of mequitazine in human plasma and urine by capillary column gas-liquid chromatography-mass spectrometry. J. Chromafogr., B, 309, 391-396 (1984)
  3. Lee, Y. J., Choi, J. H., Song, S. H., Song, C. H., Seo, C. H., Kim, D. S., Park, I. S., Choi, K. S., Na, H. K., Chung, S. J., Lee, M. H., and Shim, C. K., Development of K-BE test, a computer program for the analysis of bioequivalence. J. Kar. Pharm. Sci., 28, 223-229 (1998)
  4. Pocci, R., Dixit V., and Dixit, V. M., Solid-phase extraction and GC/MS confirmation of barbiturates from human urine. J. Anal. Taxicol., 16, 45-47 (1992) https://doi.org/10.1093/jat/16.1.45
  5. Uzan, A., Le Fur, G., and Malgouris, C., Are antihistamine sedative via a blockade of brain H1 receptors? J. Pharm. Pharmacol., 31, 701-702 (1979) https://doi.org/10.1111/j.2042-7158.1979.tb13632.x
  6. Wihl, J. A., Petersen, B. N., Petersen, L. N., Gundersen, G., Bresson, K., and Mygind, N., Effect of the non-sedative H1-receptor antagonist astemisole in perennial allergic and non-allergic rmnms. J. Allergy Clin. Immunol., 75, 720-727 (1985) https://doi.org/10.1016/0091-6749(85)90100-9
  7. Wu, A. H., Onigbinds, T. A., Wong, S. S., and Johnson, K. G., Identification of methamphtamines and over-the-counter sympathometic amines by full-scan GC-ion trap MS with electron impact and chemical ionization. J. Anal. Toxicol., 16, 137-141 (1992) https://doi.org/10.1093/jat/16.2.137
  8. Ylitalo, P., Nieminen, K., Wilen-Rosenqvist, G, Fortillan, J. B., Girault, J., Ylitalo, L., Pukander, J. S., and Karma, P. H., Serum levels and urinary excretion of mequitazine after a single oral dose. Int. J. Clin. Pharamacol Res., 9(5), 305-308 (1989)